A new way to capture when drugs are ‘cost effective’ but not ‘affordable’ looks set to be introduced in England.
What could be the impact of proposed new ‘budget impact threshold’ for drugs?
Experts discuss England’s proposed ‘fast-track’ appraisals for new treatments, plus MAAs.
Experts call for urgent development of new drug funding mechanisms.
The implications for global pharma HQs and what the UK needs to do.
The prospects for HTA Early Scientific Advice programmes.
New UK oncology drug assessment procedures examined.